Third Hematopoietic Cell Transplant for Acute Myeloid Leukemia
Mentor 1
Larisa Broglie
Start Date
28-4-2023 12:00 AM
Description
Acute Myeloid Leukemia is a common cancer among children. Treatment for AML involves conditioning and children who do not respond to this treatment are recommended a stem cell transplant. Survival rates vary with more than 50% of pediatric patients relapsing after their first transplant. A second transplant is offered to pediatric patients that are able to achieve remission after additional chemotherapy and the overall survival rate after this second transplant is 24% after 4 years and in some cases, relapses in these pediatric patients still occur. There is a lack guidance to physicians in order for them to effectively counsel patients and families regarding treatment options and outcomes following a relapse after the 2nd Hematopoietic stem cell transplant. As a result, the purpose of my study is to evaluate whether a 3rd Hematopoietic transplant could be recommended by physicians to patients who have relapsed after their second transplant. We will be looking at survival rates after 3rd HCT transplant, how myeloablative conditioning affects outcomes of 3rd HCT; this includes its association with increased transplant complications and inferior survival rates after transplant. We will also be looking at length of remission and how this is analogous with improved survival rates after transplant. We will be approaching this study from statistical perspective by analyzing data collected by the Center for International Blood and Marrow transplant Research using the Statistical Analysis System. The CIBMTR is a data base that collects data on all patients who have received stem cell transplantations. We only be analyzing data of patients that gave consent to be included in research studies. This study will impact cancer treatment by changing physicians' approach towards conditioning if it positively affects the outcomes after the third transplant.
Third Hematopoietic Cell Transplant for Acute Myeloid Leukemia
Acute Myeloid Leukemia is a common cancer among children. Treatment for AML involves conditioning and children who do not respond to this treatment are recommended a stem cell transplant. Survival rates vary with more than 50% of pediatric patients relapsing after their first transplant. A second transplant is offered to pediatric patients that are able to achieve remission after additional chemotherapy and the overall survival rate after this second transplant is 24% after 4 years and in some cases, relapses in these pediatric patients still occur. There is a lack guidance to physicians in order for them to effectively counsel patients and families regarding treatment options and outcomes following a relapse after the 2nd Hematopoietic stem cell transplant. As a result, the purpose of my study is to evaluate whether a 3rd Hematopoietic transplant could be recommended by physicians to patients who have relapsed after their second transplant. We will be looking at survival rates after 3rd HCT transplant, how myeloablative conditioning affects outcomes of 3rd HCT; this includes its association with increased transplant complications and inferior survival rates after transplant. We will also be looking at length of remission and how this is analogous with improved survival rates after transplant. We will be approaching this study from statistical perspective by analyzing data collected by the Center for International Blood and Marrow transplant Research using the Statistical Analysis System. The CIBMTR is a data base that collects data on all patients who have received stem cell transplantations. We only be analyzing data of patients that gave consent to be included in research studies. This study will impact cancer treatment by changing physicians' approach towards conditioning if it positively affects the outcomes after the third transplant.
